o2h discovery Newsflash - Winter edition 2023

Welcome to our?winter edition?newsletter.

We have been immersed in a whirlwind of activities over the last few months, extending our portfolio of services and diving deeply into a whole host of specialised domains like PROTAC, LNP’s, molecular glues, impurity synthesis, peptide synthesis/purification scale-up and the synthesis of proprietary Fragment Libraries - PHEW! We have also added new FACS and FLIPR capabilities to our spectrum of equipment in our biology team. Simultaneously, we've enjoyed actively participating in a series of impactful events and conferences because we enjoy meeting people and are insatiably curious to know what is going on in the world of science!?

With the holiday season approaching, we are excited to share a few updates from the past few months. Join us in reflecting on some of these moments that have shaped our recent adventures.

As the year comes to an end, we want to express our gratitude for your conversation, collaboration and goodwill. Wishing you and your team a Merry Christmas and a very happy New Year!

Team Capabilities Biology & Chemistry:

We extend a warm welcome to the new members of o2h discovery.

Achievements:

The highlight of the season was clinching two prestigious awards. o2h discovery won the “Most Impactful CRO of the year” Award for remarkable ESG strategy & support for early stage Biotech start-up securing funding with the o2h kickstarter programme.?We extend our heartfelt thanks to OBN (UK) Ltd for this recognition.This achievement reflects the dedication of our exceptional team, and the fruitful collaborations with ~200 global biotech and pharma partners over two decades.

Our in-house built proprietary app CITC (Chemistry in the CloudTM), won the"Best Use of Technology Award" in the Pharma Industry Awards UK 2023. CITC is the world’s first chemistry and biology project management app developed by o2h technology – a subsidiary company of o2h group, and being used by scientists and researchers at o2h discovery. Read more

Biology Capabilities:

Fragment-based drug discovery (FBDD) stands as a proven alternative to high-throughput screening (HTS). Unlike HTS, FBDD involves smaller, less complex molecules that, despite lower protein affinity, offer more atom-efficient binding. These fragments provide an efficient starting point, especially for challenging targets.

The Biacore T200 provides real-time, label-free, affinity and kinetic analysis for various types of biomolecular interactions with high sensitivity and accuracy. Our medicinal chemists have built a proprietary fragment-based drug discovery (FBDD) platform in conjunction with academic computational chemists. Read more

Chemistry Capabilities:

Building expertise in complex PROTAC synthesis and screening:

We offer comprehensive solutions for designing and synthesizing PROTAC building blocks, linkers, compound libraries, and related intermediates to support Targeted Protein Degradation.

o2h discovery offers a range of E3 ligase ligands from an “off the shelf toolbox” for the quick synthesis of PROTAC equipped with a variety of linkers for quick assembly of degrader analogues to accelerate your drug discovery and development process. To discover the full extent of the o2h PROTAC toolbox? offers & services, please visit - o2h.com/protac

o2h discovery out & about:

22nd SCI-RSC Medicinal Chemistry Symposium

Connecting with brilliant minds from innovative biotech startups and engaging with exceptional medicinal chemists and scientists was truly invigorating.

Protein Degradation & Targeting Undruggables European Congress

Our involvement in this congress provided a unique platform to collaborate with industry pioneers, advancing our understanding of the evolving landscape in drug discovery.

Discovery on Target 2023

The event offered valuable insights into the latest developments—from molecular glue to AI, and small molecules for cancer targets. It was a pleasure reconnecting with collaborators and staying abreast of industry trends.

Genesis 2024

Prashant Shah, CEO of o2h discovery, shared insights at Genesis 2023 with the theme Maximising Returns from Life Science Innovation. Genesis conference is a vibrant hub for influential leaders in the Life Science industry, fostering discussions on key trends, facilitating impactful collaborations, and shaping the future landscape of biotech innovations.

Global Bio India 2023

Sunil Shah, co-founder of o2h discovery, shared insights on funding challenges in the biotech industry. The panel emphasised the role of digital tech, showcasing the evolving landscape of biotech investments. The event aimed to showcase innovations, identify funding opportunities, and create platforms for new ideas in biotech innovations.

Diwali & Navratri Celebrations:

Amidst our professional pursuits, we took a moment to celebrate Diwali and Navratri. The festive spirit resonated through our team, fostering camaraderie and joy.

As we bid adieu to autumn, we express our gratitude for your continued support. The journey ahead promises more growth and impactful collaborations.

Be a part of our community - LinkedIn | Twitter